Bafna Pharmaceuticals Limited announced that ICRA Limited has revised the outlook on its credit ratings for bank loan facilities totaling ₹50.00 Crores from Stable to Positive. The long-term rating has been reaffirmed at [ICRA] BB+ with a revised outlook to Positive, while the short-term rating has been reaffirmed at [ICRA] A4+. This revision was communicated by ICRA via a letter dated January 23, 2026. The total bank loan facilities include term loans of ₹25.87 Crores, cash credit of ₹20.00 Crores, and unallocated limits of ₹4.13 Crores, all rated [ICRA] BB+ (Positive). The letter of credit facility of ₹5.00 Crores has been reaffirmed at [ICRA] A4+.
